Positive association seen between osteoarthritis and OAB, but not for rheumatoid arthritis or psoriatic arthritis
WEDNESDAY, March 5, 2025 (HealthDay News) — Overactive bladder (OAB) is associated with arthritis, with a positive association seen after adjustment for all covariates, according to a study published online Feb. 13 in Scientific Reports.
Yifan Sun, from Jiangnan University Medical Center in Wuxi, China, and colleagues used data from the National Health and Nutrition Examination Survey database from 2005 to 2020 to examine the possible link between OAB and arthritis. A total of 24,436 participants were included in the analyses.
The researchers identified a positive association between arthritis and OAB after adjustment for all covariates (odds ratio, 1.37; 95 percent confidence interval, 1.22 to 1.54). A positive association was seen between osteoarthritis and OAB on stratification by arthritis type (odds ratio, 1.40; 95 percent confidence interval, 1.22 to 1.62), but significant associations were not seen for rheumatoid arthritis or psoriatic arthritis (odds ratios [95 percent confidence intervals], 1.20 [0.99 to 1.46] and 1.40 [0.75 to 2.60], respectively).
“Our research suggests that patients with osteoarthritis may have a higher likelihood of developing OAB compared to those without arthritis, indicating a potential association between these two conditions,” the authors write. “Therefore, urologists should assess the musculoskeletal status of patients with OAB during diagnosis and treatment.”
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
Distinct Characteristics ID"d for Patients With Rheumatoid Conditions, Opioid Use Disorder
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status
Exposure to Air Pollutants Linked to Increased RA Disease Activity
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA
Consensus Statements Developed for Rheumatoid Arthritis-Linked Interstitial Lung Disease
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis